Detalles de la búsqueda
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
2.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385243
3.
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Eur J Nucl Med Mol Imaging
; 2024 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795120
4.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
5.
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Hematol Oncol
; 41(4): 655-662, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37246287
6.
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope.
Mycoses
; 66(1): 35-46, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36064299
7.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
8.
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
Br J Haematol
; 194(2): 378-381, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002365
9.
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.
Haematologica
; 106(7): 1828-1838, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538150
10.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Ann Hematol
; 100(10): 2547-2556, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327561
11.
Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
Hepatology
; 67(1): 48-55, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28714143
12.
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Oncologist
; 23(9): 1033-1038, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674440
13.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37222267
14.
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Haematologica
; 101(12): 1544-1552, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27515250
15.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
16.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood
; 120(1): 9-19, 2012 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22498745
17.
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Cancer Rep (Hoboken)
; 7(4): e2044, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38662362
18.
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Cancers (Basel)
; 16(6)2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539561
19.
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
Br J Haematol
; 160(2): 207-15, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23167437
20.
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
Target Oncol
; 18(6): 885-892, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37747623